Understanding Timelines and Review Milestones for CTA Approvals in the EU

Introduction: Timeframes That Define the CTA Journey

Timely approval of a Clinical Trial Application (CTA) is critical for sponsors aiming to initiate clinical trials across European Union (EU) Member States. With the enforcement of Regulation (EU) No 536/2014 and the mandatory use of the Clinical Trials Information System (CTIS), the European Medicines Agency (EMA) has established uniform review timelines applicable across all EU countries.

The CTA review process includes both scientific and ethical evaluations, coordinated across Member States. Each step in the CTA lifecycle—from validation to Part I and Part II assessments—follows fixed timelines that sponsors must understand and plan for. Missing deadlines can lead to automatic lapses or rejection of applications.

In this guide, we outline the complete set of timeline requirements under the CTR for single-country and multi-country CTA submissions.

Overview of the CTA Review Phases

Once a CTA is submitted through CTIS, it undergoes a multi-stage review process:

1. Validation Phase: Initial completeness check (10 days)
2. Part I Assessment: Coordinated scientific evaluation across countries
3. Part II Assessment: Country-specific evaluation of ethical and local aspects

The review durations differ slightly between mono-national and multi-national trials. The timeline below applies primarily to multi-country applications, which are coordinated by a Reporting Member State (RMS).

Validation Phase: 10-Day Countdown

Following submission via CTIS, the National Competent Authority (NCA) has 10 calendar days to validate the application. During this time, authorities confirm:

• Completeness of the dossier (Parts I & II)
• Correct format and document uploads
• Appropriate language and translation compliance

If the application is deemed invalid, the sponsor is notified and may resubmit. No scientific review occurs during this phase.

Coordinated Review and Member State Deadlines

Part I Assessment: Scientific Evaluation Timeline

Once validated, the Part I review phase begins under the lead of a Reporting Member State (RMS). The timeline for coordinated assessment is:

• Initial assessment period: 45 calendar days
• Optional Request for Information (RFI): Pauses the clock (maximum 12 days to respond)
• Final decision deadline: 5 days after conclusion

If an RFI is issued, the sponsor must respond within 12 days. The review clock resumes upon submission of the complete response.

Part II Assessment: Local Ethics and Site Evaluation

Part II includes ethics committee review, investigator CVs, informed consent forms, and site-level considerations. Each Concerned Member State (CMS) evaluates its own Part II independently.

The assessment period is:

• Initial period: 45 days from validation
• Optional RFI: 12-day sponsor response window
• CMS decision deadline: 5 days after RFI resolution or end of initial period

All CMS must issue their respective Part II decisions before trial authorization is granted.

Combined Outcome: CTA Authorization or Rejection

Once both Part I and Part II are complete, CTIS reflects the status as:

• Authorized: All Member States approve Part I and II
• Not Authorized: One or more Member States reject
• Authorized with Conditions: Minor issues flagged requiring further action

Sponsors receive notifications through CTIS. Authorization dates mark the legal “trial start” milestone and trigger timelines for recruitment, DSUR submission, and monitoring obligations.

CTA Withdrawal and Resubmission Timelines

Sponsors can withdraw a CTA at any point before the conclusion of the assessment. If withdrawn during validation, a full resubmission is required. If withdrawn during assessment, documents and evaluations may be reused for future submissions, depending on Member State policies.

CTIS allows labeling of submissions as “New,” “Substantial Amendment,” or “Resubmission,” which influences the corresponding review durations.

CTA Approval Timelines Summary Table

Tips for Managing CTA Timelines Efficiently

• Use CTIS notifications and dashboard for real-time tracking
• Maintain a timeline tracker with submission/resubmission dates
• Prepare RFI responses in advance to reduce turnaround delays
• Coordinate closely with country affiliates for Part II readiness

Conclusion: Regulatory Readiness is All About the Clock

Timelines are central to EU CTA success. By understanding the structured sequence from validation to authorization, sponsors can strategically plan submissions, monitor progress, and ensure compliance.

Whether launching a single-country pilot or a multi-nation pivotal study, regulatory professionals must master the clockwork of CTA approvals. The harmonized structure of the EU CTR offers predictability—but only if sponsors engage with it proactively.